10 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now

7. CRISPR Therapeutics AG (NASDAQ:CRSP)

Short Float: 30.48%

Market Cap: $5.23 Billion

Stock Upside Potential: 38.03%

Number of hedge fund holders: 32

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 27, research firm Citizens reiterated a Market Perform rating and a $60 price target on CRISPR Therapeutics AG (NASDAQ:CRSP).

The stance comes on the heels of the company maintaining a positive view of in vivo editing in cardiovascular disease. Its clinical data, presented at the European Atherosclerosis Society Congress, continues to draw strong interest in gene-editing approaches. That’s because they offer new modalities that can deliver profound and sustained lipid-lowering effects.

The company continues to advance its diversified portfolio of in vivo gene-editing programs, leveraging its proprietary liver-directed LNP delivery platform. For starters, CTX310®, a therapy targeting angiopoietin-like protein 3 (ANGPTL3), is progressing in a Phase 1b clinical trial for severe hypertriglyceridemia (sHTG) and refractory hypercholesterolemia.

CRISPR Therapeutics is also working on CTX460, for the treatment of alpha-1 antitrypsin deficiency (AATD), and CTX340, which targets angiotensinogen (AGT) for refractory hypertension.

CRISPR Therapeutics AG (NASDAQ:CRSP) develops transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. Its core focus is modifying specific genes to correct the underlying causes of serious human diseases, including genetic disorders, cancers, and autoimmune conditions.

1281292 - 11759070 - 1